The Claret European Growth Capital Fund III (‘the Fund’), a fund advised by Claret Capital Partners, provides strategic investment to Cardiac Dimensions, a pioneering medical technology company revolutionizing the field of heart failure.
3 July 2023 – The Claret European Growth Capital Fund III (“the Fund”) is pleased to announce its strategic investment in Cardiac Dimensions, a medical technology company reimagining the solutions available to patients suffering from heart failure (HF) by providing a therapy which is designed to allow patients to live longer, higher quality lives.
This partnership underscores the Fund’s commitment to advancing breakthrough medical solutions and supporting the growth of impactful healthcare ventures.
Cardiac Dimensions has gained recognition for its cutting-edge therapy, the Carillon Mitral Contour System, designed to address structural heart diseases, offering a minimally invasive solution that is designed to enhance patient outcomes and improve quality of life. The $18M facility investment from the Fund will provide Cardiac Dimensions with resources to support the US PMA EMPOWER Trial for the company’s device, Carillon, which the company is currently enrolling. In Europe, the device is approved and is a guideline directed medical therapy. It is fully reimbursed in a number of geographies and recently received its MDR certification.
“We are thrilled to support Cardiac Dimensions, a company at the forefront of medical innovation,” stated Daniel Mallon, Vice President at Claret Capital Partners. “The Fund’s investment reflects our belief in the potential of Cardiac Dimensions to make a significant impact on the lives of patients, and we are excited to contribute to their continued success.”
The Fund’s strategic investment in Cardiac Dimensions highlights its dedication to fostering the growth of healthcare companies that bring transformative solutions to market. The innovative treatments offered by Cardiac Dimensions align with the Fund’s vision of advancing healthcare technology and improving patient care across Europe.
“We are delighted to partner with The Claret European Growth Capital Fund III,” said Rick Wypych, President and CEO of Cardiac Dimensions. “This investment will enable us to accelerate our mission of providing advanced solutions to patients suffering from heart failure, giving them access to minimally invasive treatment options that have the potential to dramatically improve their lives.”